UBX1325
Phase 1Completed 0 watching 0 views this week๐ค Quiet
25
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetic Macular Edema
Conditions
Diabetic Macular Edema, Neovascular Age-related Macular Degeneration
Trial Timeline
Oct 8, 2020 โ Jan 25, 2022
NCT ID
NCT04537884About UBX1325
UBX1325 is a phase 1 stage product being developed by Unity Biotechnology for Diabetic Macular Edema. The current trial status is completed. This product is registered under clinical trial identifier NCT04537884. Target conditions include Diabetic Macular Edema, Neovascular Age-related Macular Degeneration.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04857996 | Phase 2 | Completed |
| NCT04537884 | Phase 1 | Completed |
Competing Products
20 competing products in Diabetic Macular Edema